Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesenchymal stem cell therapies - Stempeutics

Next Previous
Drug Profile

Mesenchymal stem cell therapies - Stempeutics

Alternative Names: ex-vivo cultured adult human mesenchymal stem cells - Stempeutics; ex vivo cultured adult allogenic mesenchymal stem cells - Stempeutics; ex-vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells - Stempeutics; Stempeucel; stempeucel AMI™; stempeucel CLI™; stempeucel COPD™; stempeucel CS™; stempeucel DCM™; stempeucel DM™; stempeucel LC™; stempeucel OA™

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stempeutics
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thromboangiitis obliterans
  • New Molecular Entity No
  • Available For Licensing Yes - Osteoarthritis; Peripheral ischaemia

Highest Development Phases

  • Registered Chronic limb-threatening ischemia; Osteoarthritis
  • Phase III Diabetic foot ulcer
  • No development reported Chronic obstructive pulmonary disease; Dilated cardiomyopathy; Liver cirrhosis; Myocardial infarction; Rectal fistula; Stroke; Type 2 diabetes mellitus

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Rectal-fistula in India (Parenteral)
  • 23 Aug 2023 Efficacy data from a phase III trial in Osteoarthritis released by Stempeutics
  • 19 May 2023 NCT05854615 - Trial not added as its a phase IV trial

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top